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Epithelial to Mesenchymal Transition (EMT) is an embryonic
program which is critical for the development of embryo.
Reactivation of EMT endows cancer cells with migratory and
stem cell properties, increased metastatic capacity and resistance
to chemotherapeutics1.
FOXC2, a fork head box containing transcription factor, plays a
critical role in EMT through various pathways.
Targeting FOXC2 signaling may render them sensitive to
treatments, however since it is a transcription factor it is difficult
to target.
We previously discovered that p38 kinase phosphorylates FOXC2
at the serine 367 position. This phosphorylation leads to the
stabilization of FOXC2 rendering it active and able to transform
epithelial cells to gain mesenchymal-like and cancer stem cell
properties and making them more metastatic and resistant2.
We focused on inhibiting p38 using the small molecule inhibitor
SB203580 leading to FOXC2 protein degradation and inhibition
of EMT and stem cell properties3.
D2A1 and 4T1 mouse syngeneic breast cancer cell lines are
known to express epithelial and mesenchymal markers and
display hybrid phenotype. Hybrid phenotype is associated with
high levels of stem cell properties4.
Unpublished observations in our lab have shown that treatment of
hybrid cancer cells with either TGF-β1 or TGF-β Inhibitor (SB
431532) did not seem to have an effect on inducing a
mesenchymal or epithelial state, respectively.
These cancer cells with hybrid phenotypes are harder to treat due
to their plasticity, therefore it is important to try and bring them to
a more mesenchymal or epithelial phenotype, so that they will be
easier to target. We hypothesized that inhibiting p38 will push
them to an epithelial state and make them sensitive to TGFβ1 or
TGFβ Inhibitor.

Figure 1: Dose-response curve of p38 in (A) D2. A1 and (B) 4T1 cells
Dose-response curve for the effects of p38 inhibitor SB203580 on both cell lines shown as a percent of confluency.
The values are expressed as a mean of four determinations, with error bars representing 95% CI.

CONCLUSION
• p38 Inhibitor reduces the formation of spheres due
to the inhibition of stemness and plasticity. They
are in a chaotic state when treated with p38
compared to sphere formation with the vehicles.
• p38 Inhibition alone and followed in combination
with TGF-β1 or TGF-β Inhibitor shows a dramatic
decrease in cell proliferation when compared to
DMSO and TGF-β1 or TGF-β Inhibitor alone.
• Preliminary data depicts that there is an inhibition
on invasiveness seen in D2A1 cell line. Protrusions
are reduced after treatment of p38 Inh.
• P38 appears to be the major driver in regulating
plasticity of metastatic cancer cells.
• This will prove to be vital in the clinical setting as
we can use the cancer cell plasticity as a marker to
manipulate them to our advantage and transition
them into a more stable state rendering them
sensitive to standard of care and inhibit metastasis.
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Figure 2: p38 drives cell growth inhibition in (A) D2. A1 and (B) 4T1 cells
Cell lines were pre-treated with the p38 inhibitor SB203580 (SB) using IC25 for 72 hrs., then plated
in quadruplicates in 96-well plate, allowed to recover for 24 hrs. and treated with p38 alone or in combination
as indicated in the figure. Single treatments, DMSO (.01%), TGF-β (5ng/mL), SB231532 (5 ng/mL) were
included as well. Plate was put in incucyte and percent confluency was measured.
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Adapted from: Wang, Teng, Lei Zheng, Qian Wang, and Yan-Wei Hu. Clinica Chimica Acta. Elsevier, 16 Jan. 2018.

Adapted from: Li, Mingzhe, Xin Bu, Bolei Cai, Ping Liang, Kai Li, Xuan Qu, and Liangliang Shen. Oncology Reports. Spandidos
Publications, 01 Feb. 2019.

METHODS

Figure 3: A & B represent images of mammospheres in their respective wells with treatment. The stemness
of D2A1 & 4T1. Stemness was drastically affected with the addition of the p38 Inhibitor as seen in the images
above. The Vehicle & TGF-β1 or TGF-β Inhibitor alone seemed to form large spheres, however once treated with
p38 Inhibitor, there was a drastic decrease in sphere size and count.
P38 drives cell growth inhibition in (C) D2.A1 and (D) 4T1 cells
Cell lines were pre-treated with the p38 inhibitor SB203580 (SB) using IC25 for 72hrs., then plated in
quadruplicates in 96-well plate using mammospheres media and low attachment plates, allowed to recover for
24hrs. And treated with p38 alone or in combination as indicated in figure. Single treatments, DMSO (.01%),
TGF-β (5ng/mL), SB231532 (5 ng/mL) were included as well. Mammospheres were allowed to form for up to 9
days. Spheres were counted as depicted above.

• Expand to other hybrid breast cancer cell
lines to verify the effect of p38 inhibition
on plasticity.
• Check for epithelial & mesenchymal
markers via western blots.
• Conduct immunofluorescence staining of
epithelial & mesenchymal markers.
• Perform acini formation assay assessing
the cell morphology after treatment.
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